Chiara Lazzari Selected Research

Melanoma (Melanoma, Malignant)

9/2021	Role of stereotactic radiosurgery for the treatment of brain metastasis in the era of immunotherapy: A systematic review on current evidences and predicting factors.
1/2014	Antitumor activity of sorafenib and imatinib in a patient with thymic carcinoma harboring c-KIT exon 13 missense mutation K642E.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Chiara Lazzari Research Topics

Disease

29	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 04/2022 - 01/2009
20	Neoplasms (Cancer) 04/2022 - 01/2005
8	Lung Neoplasms (Lung Cancer) 04/2022 - 08/2014
4	Disease Progression 11/2021 - 09/2013
3	Brain Neoplasms (Brain Tumor) 09/2021 - 01/2016
2	Neoplasm Metastasis (Metastasis) 04/2022 - 09/2021
2	Melanoma (Melanoma, Malignant) 09/2021 - 01/2014
2	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 12/2018 - 10/2018
2	Gastrointestinal Stromal Tumors (Gastrointestinal Stromal Tumor) 01/2015 - 01/2014
1	Inflammation (Inflammations) 03/2021
1	Acute-Phase Reaction 03/2021
1	Bell Palsy (Bell's Palsy) 03/2019
1	Myasthenia Gravis 03/2019
1	Nervous System Diseases (Neurological Disorders) 03/2019
1	Polyneuropathies (Polyneuropathy) 03/2019
1	Brain Diseases (Brain Disorder) 03/2019
1	Circulating Neoplastic Cells 04/2018
1	Bradycardia 01/2015
1	Fatigue 01/2015
1	Edema (Dropsy) 01/2015
1	Vision Disorders (Hemeralopia) 01/2015
1	Cardiotoxicity 01/2015
1	Neutropenia 06/2014
1	Thymoma (Thymic Carcinoma) 01/2014
1	Adenocarcinoma 09/2013
1	Ataxia (Dyssynergia) 08/2009
1	Pancreatic Neoplasms (Pancreatic Cancer) 01/2009
1	Colorectal Neoplasms (Colorectal Cancer) 01/2009

Drug/Important Bio-Agent (IBA)

10	ErbB Receptors (EGF Receptor)IBA 01/2022 - 01/2009
10	Tyrosine Kinase InhibitorsIBA 01/2022 - 01/2012
5	Biomarkers (Surrogate Marker)IBA 03/2021 - 06/2014
5	Immune Checkpoint InhibitorsIBA 09/2020 - 01/2017
4	Anaplastic Lymphoma KinaseIBA 01/2018 - 01/2015
4	CrizotinibIBA 01/2016 - 03/2014
3	osimertinibIBA 04/2022 - 04/2018
3	Biological ProductsIBA 04/2021 - 02/2016
3	Circulating Tumor DNAIBA 01/2019 - 04/2018
3	Erlotinib Hydrochloride (CP 358,774)FDA Link 02/2015 - 06/2014
2	Proteins (Proteins, Gene)FDA Link 04/2021 - 08/2009
2	Imatinib Mesylate (Gleevec)FDA Link 01/2015 - 01/2014
2	Phosphotransferases (Kinase)IBA 01/2015 - 08/2009
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2022
1	AutoantibodiesIBA 01/2022
1	tocilizumab (atlizumab)FDA Link 11/2021
1	AntibodiesIBA 01/2021
1	NivolumabIBA 03/2019
1	SuspensionsIBA 03/2019
1	pembrolizumabIBA 03/2019
1	Temozolomide (Temodar)FDA LinkGeneric 12/2018
1	veliparibIBA 12/2018
1	RNA (Ribonucleic Acid)IBA 11/2018
1	Epidermal Growth Factor (EGF)IBA 11/2018
1	PlatinumIBA 10/2018
1	human CNGRC fusion protein tumor necrosis factor-alphaIBA 10/2018
1	Doxorubicin (Adriamycin)FDA LinkGeneric 10/2018
1	B7-H1 AntigenIBA 01/2018
1	LigandsIBA 02/2017
1	Angiogenesis InhibitorsIBA 01/2017
1	ChromatinIBA 02/2016
1	ceritinibIBA 06/2015
1	EGF Family of ProteinsIBA 02/2015
1	EnzymesIBA 01/2015
1	AfatinibIBA 08/2014
1	Gefitinib (Iressa)FDA Link 08/2014
1	Sorafenib (BAY 43-9006)FDA Link 01/2014
1	Protein Kinases (Protein Kinase)IBA 07/2009
1	Integrin beta4IBA 07/2009
1	Integrin alpha6beta4IBA 07/2009
1	Monoclonal AntibodiesIBA 01/2009
1	Pyrimidine DimersIBA 01/2005

Therapy/Procedure

10	Therapeutics 04/2022 - 09/2013
8	Drug Therapy (Chemotherapy) 01/2022 - 06/2014
6	Immunotherapy 09/2021 - 01/2017
2	Radiotherapy 01/2018 - 09/2013
1	Craniotomy 04/2022
1	Lymph Node Excision (Lymph Node Dissection) 04/2022
1	Combined Modality Therapy 04/2022
1	Precision Medicine 01/2021
1	Aftercare (After-Treatment) 12/2012
1	Lasers (Laser) 01/2012